European Case Law Identifier: | ECLI:EP:BA:2015:T239711.20151015 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 15 October 2015 | ||||||||
Case number: | T 2397/11 | ||||||||
Application number: | 04710031.8 | ||||||||
IPC class: | C07D 239/94 A61K 31/517 A61P 35/00 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | POLYMORPH OF {6,7-BIS(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL}-(3E) | ||||||||
Applicant name: | F. Hoffmann-La Roche AG | ||||||||
Opponent name: | Teva Pharmaceutical Industries LTD. | ||||||||
Board: | 3.3.01 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Clarity (yes) Extension of protection conferred (no) Novelty: main, auxiliary request 1 (no); auxiliary request 2 (yes) Remittal, auxiliary request 2 |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t112397eu1.html
Date retrieved: 17 May 2021